Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMU-131 + ramucirumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Imugene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intramuscular (IMU-131), Intravenous (ramucirumab, Paclitaxel)
01
Overview
IMU-131 + ramucirumab + paclitaxel is an experimental combination therapy under investigation for advanced or metastatic HER2/neu-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma. IMU-131 (also known as HER-Vaxx) is a B-cell cancer vaccine designed to stimulate an immune response against the HER2/neu receptor. Ramucirumab is a monoclonal antibody targeting VEGFR-2, inhibiting angiogenesis, and paclitaxel is a taxane-class chemotherapeutic that stabilizes microtubules, disrupting cell division. The combination aims to leverage immune activation, inhibition of tumor angiogenesis, and cytotoxic chemotherapy. The regimen is studied mainly in patients who have progressed after trastuzumab therapy[1].
- Brand names
- HER-Vaxx
- Other names
- IMU-131 + ramucirumab + paclitaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IMU-131 + ramucirumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMU-131 + ramucirumab + paclitaxel.